Insights and Ideas

Whitepapers, case studies, and other helpful resources to support outcomes-based healthcare

Ask Procured Health: Should sugammadex use be restricted?

In talking to healthcare leaders about drug utilization, I’ve fielded many questions concerning the application of clinical evidence to specific drugs and drug categories. I address one popular topic below.

DEAR PROCURED HEALTH: While my hospital currently limits sugammadex usage, our anesthesiologists have been impressed by the clinical results and want to use it more broadly for reversal of neuromuscular blockade (NMB) after surgery. However, sugammadex is priced two to three times higher than neostigmine. Should we reconsider our restrictions? SORTING OUT SUGAMMADEX


"Value analysis as a stand-alone governance process is failing...": An Interview with Procured Health

During a recent in-depth interview with Value Analysis Utilization and Management Magazine, my Procured Health colleague Gina Thomas and I discussed some critical observations we’ve made based on our work with health systems around the country. including the importance of clinical evidence to drive decision-making and the role of physicians in eliminating unwarranted clinical variation.


Rising Drug Costs: Not Just the Pharmacy Department’s Problem

Nov. 28, 2017

A few months back, I witnessed a conference presenter invite a large group of hospital pharmacy leaders to raise their hands if drug spend was one of their health system’s top three concerns. The room filled with laughter and someone shouted, “Top 10 if you’re lucky!”

This cynicism is disheartening, but not surprising. While every week brings more headlines about outrageously expensive new drugs, exorbitant price hikes for lifesaving treatments and shrinking reimbursements, these issues have often been viewed as “pharmacy’s problem.” Of course, the truth is far more nuanced and complex with wide-ranging impact on patients, clinicians and hospital leaders.


Unpacking ORBITA: What the Controversial Stent Study Really Means

Recently published results from the ORBITA trial call into question whether percutaneous coronary intervention (PCI) is actually effective at reducing angina, or whether the reduction in chest pain associated with the procedure is purely due to the placebo effect. Below, Procured Health experts Elizabeth Nee and Erin Gavin, PharmD, look past the headlines and hand wringing.


Webinar: Driving Orthopedic Care Decisions with Clinical Evidence

Increasing financial pressures and alternative payment models are challenging providers to develop more cost-effective strategies for joint replacement procedures. In this environment, an evidence-based approach to device selection is essential for reducing unnecessary care variation, lowering costs and improving patient care. 

This presentation will highlight the importance of appropriate implant selection and utilization of ancillary devices in managing costs and provide strategies for successfully optimizing inpatient and post-acute care in a value-based environment.

Key questions we'll address include: 

• How will value-based care and alternative payment models impact orthopedics?

• When does clinical evidence support the use of premium implants and ancillary products?

• How does clinical evidence help achieve cost and quality targets in the inpatient and post-acute care settings? 


Ask Procured Health: What evidence supports using heparin for PCI rather than bivalirudin?

In talking to healthcare leaders about drug utilization, I’ve fielded many questions concerning the application of clinical evidence to specific drugs and drug categories. I address one popular topic below.

DEAR PROCURED HEALTH: Heparin is much less expensive than bivalirudin. What evidence can I use to support standardizing to it as our primary anticoagulant for percutaneous coronary intervention (PCI)? – HOPING FOR HEPARIN


CPES 2017: What's Top of Mind for Pharmacy Leaders?

Bonnie Lai, PhD, Vice President of Pharmacy Solutions, recently attended the 2017 annual meeting of the Council of Pharmacy Executives and Suppliers (CPES). Below, she answers a few questions about key topics.


Evidence Insight Spotlight: Neuromonitoring in Spinal Procedures

Intraoperative neuromonitoring (IONM) tracks a patient's neural pathways during spinal surgery, alerting physicians to adverse neurological changes. The IONM was introduced as a way to prevent postoperative neurological deficits by allowing physicians to perform corrective interventions intraoperatively. 

Download this evidence insight to: 

• Read the rationale for using IONM in spinal procedures

• View a table showing for which procedures IONM is and is not supported  

• Learn how to avoid overuse at your organization 


Becoming HIPAA Compliant: Our Investment in the Future of Healthcare

Oct. 11, 2017 hipaa Best Practices About

Peter Saul, director of emerging solutions, describes why we went through the process to become compliant with the Health Insurance Portability and Accountability Act of 1996, better known as HIPAA. 


Vascular Disease Highlights from the Chicago EndoVascular Conference: A Chat with Our Experts

Oct. 3, 2017 Medical Devices

Procured Health medical device experts Vikram Karandikar and Kelsey Peterson recently attended the Chicago EndoVascular Conference (CVC). Below they trade thoughts about some recent advances in the field.